Asbestos-Related Lung and Pleural Disease
On this page
Direct answer
Asbestos-related disease covers pleural plaques, asbestosis, benign asbestos pleural effusion, mesothelioma and lung cancer, all arising from inhaled asbestos fibres. Pleural plaques are the commonest manifestation and mark exposure rather than malignancy, whereas mesothelioma and lung cancer carry the greatest morbidity. Latency runs for decades, so a detailed occupational history is the single most important part of the assessment.
What you must remember
- Pleural plaques: well-defined, often calcified plaques on the parietal pleura, usually bilateral and mostly asymptomatic, and they do not turn into mesothelioma.
- Asbestosis: diffuse interstitial fibrosis with lower-zone predominance, basal crackles, restrictive physiology and a reduced DLCO.
- Benign effusion: an exudate that can appear early after exposure, often resolves, and may recur.
- Mesothelioma: a pleural tumour with long latency, often presenting with chest pain, effusion and weight loss, carrying a poor prognosis.
- Immunostaining: calretinin and WT1 favour mesothelioma, while CEA, BerEP4 and MOC-31 favour adenocarcinoma.
- Smoking synergy: asbestos and smoking act together to raise the lung cancer risk far more than either alone.
- Diagnosis: mesothelioma is confirmed by pleural biopsy, often thoracoscopic, because pleural fluid cytology is frequently negative.
A classification by latency and finding
Asbestos-related disorders differ in latency, site and prognosis, and the table below separates the main entities. Exposure history decides how the imaging is read.
| Entity | Latency after exposure | Typical finding | Clinical point |
|---|---|---|---|
| Pleural plaques | Often 20 years or more | Bilateral parietal plaques | Marker of exposure, usually silent |
| Asbestosis | Usually 10 to 20 years | Basal fibrosis, crackles, low DLCO | Restrictive, no specific cure |
| Benign effusion | Often early | Exudate, sometimes eosinophilic | May resolve or recur |
| Diffuse pleural thickening | Years after exposure | Circumferential thickening | Can cause significant restriction |
| Mesothelioma | Usually 20 to 50 years | Pleural mass, effusion, chest pain | Poor prognosis |
| Lung cancer | Usually decades | Central or peripheral mass | Risk multiplied by smoking |
Only mesothelioma and lung cancer are malignant, so a plaque on imaging does not by itself mandate treatment. The interpretation depends on the exposure history and the pattern together. Ask about the industry, the duration of exposure, the use of protective equipment, and any household exposure from a worker's clothing, because a family member can be exposed without ever entering the workplace.
Where the exam tries to catch you
Students lose marks by treating every pleural abnormality in an exposed worker as the same disease.
- Trap: calling pleural plaques premalignant for mesothelioma Correct: plaques are benign markers of exposure and do not transform into mesothelioma.
- Trap: placing asbestosis in the pleura Correct: asbestosis is parenchymal fibrosis, lower-zone predominant, with basal crackles.
- Trap: diagnosing mesothelioma from pleural fluid cytology alone Correct: a negative sample does not exclude it, so thoracoscopic biopsy with immunohistochemistry is required.
- Trap: dismissing a pleural mass as tuberculosis in an exposed worker Correct: a mass with an exposure history should prompt biopsy for mesothelioma.
Frequently asked questions
Which finding on imaging indicates asbestos exposure rather than malignancy?
Bilateral, calcified pleural plaques on the parietal pleura, usually over the lower chest wall and diaphragm, indicate asbestos exposure. They are benign and usually asymptomatic, so their presence does not prove mesothelioma or lung cancer.
What is the typical latency for mesothelioma after asbestos exposure?
Mesothelioma usually appears 20 to 50 years after asbestos exposure, which is why the occupational history must reach back decades. A long latency period is therefore not evidence against asbestos as the cause.
Which immunohistochemical markers help distinguish mesothelioma from adenocarcinoma?
Calretinin and WT1 are positive in mesothelioma, while CEA, BerEP4 and MOC-31 are positive in adenocarcinoma. A panel combining these markers helps separate the two on pleural biopsy.
How does smoking change the lung cancer risk in asbestos-exposed workers?
Smoking and asbestos act synergistically, so an exposed smoker has a risk of lung cancer far greater than the sum of the two alone. Smoking cessation is therefore a priority for any asbestos-exposed worker.
Why is asbestosis usually restrictive with a reduced DLCO?
Asbestosis causes diffuse interstitial fibrosis that stiffens the lungs and reduces the alveolar surface available for gas transfer. The result is a restrictive pattern on spirometry with a disproportionately low DLCO.